AtriCure, Inc. reported fourth quarter and full year 2025 financial results, with Q4 revenue of $140.5 million (13.1% YoY growth) and full year revenue of $534.5 million (14.9% YoY growth). The company also issued 2026 financial guidance projecting revenue of $600 million to $610 million and positive adjusted EBITDA of $80 million to $82 million.
Key takeaways
Fourth Quarter 2025 worldwide revenue was $140.5 million, an increase of 13.1% year over year.
Full Year 2025 worldwide revenue was $534.5 million, an increase of 14.9% year over year.
Fourth Quarter 2025 net income was $1.8 million, or $0.04 per share, compared to a net loss of $15.6 million in the prior year period.
Full Year 2025 net loss was $11.4 million, or $0.24 per share, an improvement from a net loss of $44.7 million in 2024.
Management projects full year 2026 revenue guidance of $600 million to $610 million, representing 12% to 14% growth.
Full year 2026 adjusted EBITDA is expected to be $80 million to $82 million with positive net income.
Conference call scheduled for February 17, 2026 at 4:30 p.m. Eastern Time.